2023
Impact of school‐supervised ultra‐long‐acting basal insulin injections on ketosis in youth with T1D and elevated haemoglobin A1c: A pilot study
Nally L, Sherr J, Tichy E, Weyman K, Urban A, Shabanova V, McCollum S, Steffen A, Tamborlane W, Van Name M. Impact of school‐supervised ultra‐long‐acting basal insulin injections on ketosis in youth with T1D and elevated haemoglobin A1c: A pilot study. Diabetic Medicine 2023, 40: e15123. PMID: 37078999, PMCID: PMC10524154, DOI: 10.1111/dme.15123.Peer-Reviewed Original ResearchConceptsBasal insulin injectionsDiabetic ketoacidosisPercent of participantsBlood β-hydroxybutyrateInsulin injectionsBasal insulin dosesBasal insulin typeType 1 diabetesManagement of youthDegludec groupSignificant ketosisAcute complicationsBasal insulinInsulin dosesRisk of ketosisInjected insulinHigher hemoglobinInsulin administrationElevated hemoglobinInsulin typeKetone levelsHigh riskSchool nursesDegludecLarger sample size
2022
When insulin isn’t enough: targeting glucagon in type 1 diabetes
Van Name M, Sherr J. When insulin isn’t enough: targeting glucagon in type 1 diabetes. Nature Medicine 2022, 28: 2007-2008. PMID: 36192555, DOI: 10.1038/s41591-022-02019-3.Commentaries, Editorials and LettersSafety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial
Sherr JL, Bode BW, Forlenza GP, Laffel LM, Schoelwer MJ, Buckingham BA, Criego AB, DeSalvo DJ, MacLeish SA, Hansen DW, Ly TT, Sherr J, Weyman K, Tichy E, VanName M, Brei M, Zgorski M, Steffen A, Carria L, Bode B, Busby A, Forlenza G, Wadwa R, Slover R, Cobry E, Messer L, Laffel L, Isganaitis E, Ambler-Osborn L, Freiner E, Turcotte C, Volkening L, Schoelwer M, Brown S, Krauthause K, Emory E, Oliveri M, Buckingham B, Ekhlaspour L, Kingman R, Criego A, Schwartz B, Gandrud L, Grieme A, Hyatt J, DeSalvo D, McKay S, DeLaO K, Villegas C, MacLeish S, Wood J, Kaminski B, Casey T, Campbell W, Behm K, Adams R, Hansen D, Stone S, Bzdick S, Bulger J, Agostini L, Doolittle S, Kivilaid K, Kleve K, Ly T, Dumais B, Vienneau T, Huyett L, Lee J, O’Connor J, Benjamin E. Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care 2022, 45: 1907-1910. PMID: 35678724, PMCID: PMC9346983, DOI: 10.2337/dc21-2359.Peer-Reviewed Original ResearchConceptsInsulin delivery systemsSingle-arm studyLong-term complicationsMulticenter clinical trialType 1 diabetesSensor glucose levelsYoung childrenBaseline data collectionReduced hypoglycemiaDiabetic ketoacidosisGlycemic targetsUsual therapyGlycemic measuresSevere hypoglycemiaDelivery systemStudy endGlycemic outcomesClinical trialsGlucose levelsType 1HypoglycemiaInvestigational systemDlChildrenStudy phaseLong-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study
Van Name MA, Kanapka LG, DiMeglio LA, Miller KM, Albanese-O’Neill A, Commissariat P, Corathers SD, Harrington KR, Hilliard ME, Anderson BJ, Kelley JC, Laffel LM, MacLeish SA, Nathan BM, Tamborlane WV, Wadwa RP, Willi SM, Williams KM, Wintergerst KA, Woerner S, Wong JC, DeSalvo DJ. Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study. Journal Of Diabetes Science And Technology 2022, 17: 976-987. PMID: 35343269, PMCID: PMC10348002, DOI: 10.1177/19322968221084667.Peer-Reviewed Original ResearchConceptsFamily behavioral interventionsContinuous glucose monitoringBlood glucose monitoringCGM useYoung childrenGlucose monitoringOne-year resultsType 1 diabetesContinuous glucose monitor useHemoglobin A1cCGM groupGlycemic outcomesType 1Behavioral interventionsExtension phaseBGM groupMonitor useOne-year studyCGM technologyDiabetes technologyGlycemiaHypoglycemiaChildrenBehavioural supportGroup
2021
Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observational real‐world cohort study
Dovc K, Van Name M, Bizjan B, Rusak E, Piona C, Yesiltepe‐Mutlu G, Mentink R, Frontino G, Macedoni M, Ferreira SH, Serra‐Caetano J, Galhardo J, Pelicand J, Silvestri F, Sherr J, Chobot A, Biester T, Group F. Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observational real‐world cohort study. Diabetes Obesity And Metabolism 2021, 24: 564-569. PMID: 34820985, PMCID: PMC9306649, DOI: 10.1111/dom.14607.Peer-Reviewed Original Research
2020
Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers
Ebekozien O, Agarwal S, Noor N, Albanese-O’Neill A, Wong JC, Seeherunvong T, Sanchez J, DeSalvo D, Lyons SK, Majidi S, Wood JR, Acharya R, Aleppo G, Sumpter KM, Cymbaluk A, Shah NA, Van Name M, Cruz-Aviles L, Alonso GT, Gallagher MP, Sanda S, Feuer AJ, Cossen K, Rioles N, Jones NY, Kamboj MK, Hirsch IB. Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers. The Journal Of Clinical Endocrinology & Metabolism 2020, 106: 1755-1762. PMID: 33410917, PMCID: PMC7928931, DOI: 10.1210/clinem/dgaa920.Peer-Reviewed Original ResearchConceptsNH Black patientsLaboratory-confirmed COVID-19NH-White patientsDiabetic ketoacidosisType 1 diabetesNH blacksBlack patientsNH whitesWhite patientsHispanic patientsPotential confoundersLaboratory-confirmed coronavirus disease 2019COVID-19Multivariable logistic regression analysisUS clinical centersCross-sectional studyCOVID-19 infectionCoronavirus disease 2019Logistic regression analysisRace/ethnicity groupsMedian HbA1cSerious complicationsDKA eventsPatient factorsT1D patientsA Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes.
Laffel L, Harrington K, Hanono A, Naik N, Ambler-Osborn L, Schultz A, DiMeglio L, Woerne S, Jolivette H, Ismail H, Tebbe M, Newman A, Legge M, Tamborlane W, Van Name M, Weyman K, Finnegan J, Steffen A, Zgorski M, DeSalvo D, Hilliard M, DeLaO K, Xie C, Levy W, Wadwa R, Forlenza G, Majidi S, Alonso G, Weber I, Clay M, Simmons E, Nathan B, Sunni M, Sweet J, Pappenfus B, Kogler A, Ludwig M, Nelson B, Street A, Weingartner D, Albanese-O’Neill A, Haller M, Adams J, Cintron M, Thomas N, Kelley J, Simmons J, William G, Brendle F, Goland R, Williams K, Gandica R, Pollak S, Casciano E, Robinson E, Willi S, Minnock P, Olivos D, Carchidi C, Grant B, Wong J, Adi S, Corathers S, Sheanon N, Fox C, Weis T, MacLeish S, Wood J, Casey T, Campbell W, McGuigan P, Wintergerst K, Watson S, Kingery S, Pierce G, Ruch H, Rayborn L, Rodriguez-Luna M, Deuser A. A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes. Diabetes Care 2020, 44: 464-472. PMID: 33334807, PMCID: PMC9162100, DOI: 10.2337/dc20-1060.Peer-Reviewed Original ResearchConceptsType 1 diabetesBlood glucose monitoringContinuous glucose monitoringFamily behavioral interventionsGlucose monitoringFingerstick blood glucose monitoringBehavioral interventionsSevere hypoglycemic eventsDays/weekYears of ageFear of hypoglycemiaYoung childrenTreatment group comparisonsChildren ages 2Very Young ChildrenHypoglycemic eventsCGM groupDiabetes burdenClinical trialsGlycemic outcomesGlucose levelsPrimary analysisDiabetesBGM groupPercent timeA Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention
Nally LM, Wagner J, Sherr J, Tichy E, Weyman K, Ginley MK, Zajac K, Desousa M, Shabanova V, Petry NM, Tamborlane WV, Van Name M. A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention. Endocrine Practice 2020, 27: 545-551. PMID: 34120699, PMCID: PMC8206518, DOI: 10.1016/j.eprac.2020.11.017.Peer-Reviewed Original Research‘I’m essentially his pancreas’: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes
PV C, KR H, AL W, KM M, ME H, M V, DJ D, WV T, BJ A, LA D, LM L. ‘I’m essentially his pancreas’: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes. 2020 DOI: 10.1530/ey.17.10.10.Peer-Reviewed Original ResearchAlcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange
Alessi SM, Foster NC, Rash CJ, Van Name MA, Tamborlane WV, Cengiz E, Polsky S, Wagner J. Alcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange. Canadian Journal Of Diabetes 2020, 44: 501-506. PMID: 32792103, DOI: 10.1016/j.jcjd.2020.06.005.Peer-Reviewed Original ResearchConceptsBody mass indexSevere hypoglycemiaFormer drinkersLower oddsAlcohol consumptionNonbinge drinkersType 1Current binge drinkersPresence of neuropathyDiabetes-related distressDiabetes-related outcomesType 1 diabetesCross-sectional studyYears of ageNon-Hispanic whitesDiabetic ketoacidosisRecent severe hypoglycemiaMedical chartsClinical outcomesMass indexProspective studyDiabetes distressBlood glucoseBinge drinkersDrinking status67-OR: Benefit of Reduced Hypoglycemia with Continuous Glucose Monitoring (CGM) Is Sustained through 12 Months among Young Children with Type 1 Diabetes (T1D)
VAN NAME M, MILLER K, KANAPKA L, TAMBORLANE W, DIMEGLIO L. 67-OR: Benefit of Reduced Hypoglycemia with Continuous Glucose Monitoring (CGM) Is Sustained through 12 Months among Young Children with Type 1 Diabetes (T1D). Diabetes 2020, 69 DOI: 10.2337/db20-67-or.Peer-Reviewed Original ResearchContinuous glucose monitoringCGM groupBlood glucose monitoringBehavioral interventionsEfficacy of CGMGlucose monitoringFamily behavioral interventionsType 1 diabetesYoung childrenEisai Inc.MannKind CorporationReduced hypoglycemiaSanofi USLess hypoglycemiaMedian ageMedian timeHarry B. Helmsley Charitable TrustTrial completionCGM useHypoglycemiaDurable reductionInsulin pumpBGM groupSimilar reductionWeeksTransforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model
Van Name M, Klingensmith G, Nelson B, Wintergerst K, Mitchell J, Norris K, Tamborlane W, Clements M, Hannon T, Shoemaker A, Wood J, Gal R. Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model. Diabetes Technology & Therapeutics 2020, 22: 330-336. PMID: 31859529, PMCID: PMC7869879, DOI: 10.1089/dia.2019.0448.Peer-Reviewed Original ResearchConceptsPediatric Diabetes ConsortiumType 2 diabetesClinical centersCoordinating CenterPediatric treatment centerPediatric type 1 diabetesPhase 3 trialType 2 Diabetes StudyType 1 diabetesPediatric Type 2Diabetes-related studiesTreatment of youthPivotal trialsRandomized subjectsDiabetes StudyStudy protocolClinical trialsContract research organizationsConsortium modelTreatment centersType 2DiabetesNew drugsTrialsEnrollment strategiesSources and Valence of Information Impacting Parents' Decisions to Use Diabetes Technologies in Young Children <8 Years Old with Type 1 Diabetes
Commissariat P, Whitehouse A, Hilliard M, Miller KM, Harrington KR, Levy W, DeSalvo DJ, Van Name M, Anderson B, Tamborlane W, DiMeglio LA, Laffel L. Sources and Valence of Information Impacting Parents' Decisions to Use Diabetes Technologies in Young Children <8 Years Old with Type 1 Diabetes. Diabetes Technology & Therapeutics 2020, 22: 697-700. PMID: 32077755, PMCID: PMC7718841, DOI: 10.1089/dia.2019.0497.Peer-Reviewed Original ResearchConceptsType 1 diabetesDiabetes technologyCare providersYoung childrenDiabetes care providersHealth care providersCaregivers of childrenDiabetes technology useSubset of parentsDiabetesCare optionsType 1Most parentsUnderwent content analysisChildrenParents' decisionsProvidersSemi-structured interviewsParentsYearsChildren and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2019
“I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes
Commissariat PV, Harrington KR, Whitehouse AL, Miller KM, Hilliard ME, Van Name M, DeSalvo DJ, Tamborlane WV, Anderson BJ, DiMeglio LA, Laffel LM. “I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes. Pediatric Diabetes 2019, 21: 377-383. PMID: 31808586, PMCID: PMC7830825, DOI: 10.1111/pedi.12956.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlycemic controlDiabetes burdenSecondary caregiversEmotional burdenChildren's glycemic controlYoung childrenCare of childrenAge 5.2Parents' perceptionsCaregivers' knowledgeClinical centersSemi-structured qualitative interviewsDiabetesDiabetes educationParental burdenHealthcare providersAge groupsInsulin pumpParents' burdenT1DChildren's qualityChild's diabetesParents' knowledgeParents' confidenceGreater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring
Van Name MA, Miller KM, Commissariat PV, Whitehouse AL, Harrington KR, Anderson BJ, Mantravadi MG, Levy W, DeSalvo DJ, Tamborlane WV, Hilliard ME, Laffel LM, DiMeglio LA. Greater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring. Diabetic Medicine 2019, 36: 1508-1510. PMID: 31295359, PMCID: PMC7027357, DOI: 10.1111/dme.14074.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringGlucose targetsParental comfortGlucose monitoringYoung childrenPharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugsImpact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2Degludec
2017
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi A, Sherr J, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane W. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2017, 103: 1088-1094. PMID: 29211871, PMCID: PMC6276715, DOI: 10.1210/jc.2017-02265.Peer-Reviewed Original ResearchConceptsMixed meal tolerance testPlasma glucagon responseWeeks of treatmentGlucagon responsePostprandial hyperglycemiaMeal-stimulated increaseWeeks of therapyPlasma glucagon levelsType 1 diabetesPlasma glucose curveBolus insulin administrationMixed meal feedingDl/minGlucagon curveAdjunctive treatmentGlucagon levelsPlasma glucagonTolerance testIncremental areaInsulin administrationGlucose curvePostmeal hyperglycemiaLiraglutideGlucose responsePretreatment responsesAltered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, Sherr JL. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. Diabetes Technology & Therapeutics 2017, 19: 618-622. PMID: 29068709, PMCID: PMC5689123, DOI: 10.1089/dia.2017.0267.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsPlasma glucoseType 1 diabetesDiabetic ketoacidosisFree fatty acidsCANA treatmentBasal insulinGlucagon levelsMetabolic decompensationPlasma insulinInfusion site problemsCotransporter 2 inhibitorsBaseline plasma glucoseFailure of patientsBasal insulin infusionAdjunctive treatmentRate of ketogenesisSGLT2 inhibitorsT1D patientsT1D participantsInsulin infusionMagnitude of increasePG levelsSuspension studiesΒ-hydroxybutyrate